Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932698 · ClinicalTrials.gov registry record · Phase 1
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00932698 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00932698, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will determine the safety profile, tolerability, and maximum tolerated dose (MTD) and disease response of Ixazomib administered orally in participants with relapsed and/or refractory multiple myeloma.
Interventions
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-10-12 |
| Est. Completion | 2017-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00932698
The ClinicalTrials.gov registry entry for NCT00932698 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ixazomib is the first listed.
NCT00932698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00932698 about?
NCT00932698 is a clinical study titled "Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma". This study will determine the safety profile, tolerability, and maximum tolerated dose (MTD) and disease response of Ixazomib administered orally in participants with relapsed and/or refractory multiple myeloma.
What is the current status of trial NCT00932698?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2009-10-12. Estimated completion is 2017-05-23.
What interventions are being tested in trial NCT00932698?
The interventions under investigation include: Ixazomib (DRUG).
Who is sponsoring clinical trial NCT00932698?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.